Mutations in IDH1 and IDH2 (encoding isocitrate dehydrogenase 1 and 2) drive the development of gliomas and other human malignancies. Mutant IDH1 induces epigenetic changes that promote tumorigenesis, but the scale and reversibility of these changes are unknown. Here, using human astrocyte and glioma tumorsphere systems, we generate a large-scale atlas of mutant-IDH1-induced epigenomic reprogramming. We characterize the reversibility of the alterations in DNA methylation, the histone landscape, and transcriptional reprogramming that occur following IDH1 mutation. We discover genome-wide coordinate changes in the localization and intensity of multiple histone marks and chromatin states. Mutant IDH1 establishes a CD24 + population with a proliferative advantage and stem-like transcriptional features. Strikingly, prolonged exposure to mutant IDH1 results in irreversible genomic and epigenetic alterations. Together, these observations provide unprecedented high-resolution molecular portraits of mutant-IDH1-dependent epigenomic reprogramming. These findings have substantial implications for understanding of mutant IDH function and for optimizing therapeutic approaches to targeting IDH-mutant tumors.
M
utations in IDH1 and IDH2 are found in over 80% of lowergrade gliomas (LGGs) and secondary glioblastomas 1, 2 . IDH1 mutations commonly occur at codon 132 and lead to the production of 2-hydroxyglutarate (2HG) 3 . In experimental models, introduction of mutant IDH1 and 2HG production lead to global DNA hypermethylation, histone methylation alterations, and differentiation block [4] [5] [6] . Pharmacological lowering of 2HG levels with inhibitors selective for mutant IDH does not completely reverse mutant-IDH-dependent epigenetic changes in vitro or in vivo, at least for the treatment durations tested 7, 8 . A definitive therapeutic effect for IDH inhibitors is yet to be established, as both growth suppression and acceleration have been observed upon treatment in various solid tumor models 7, 8 . These studies raise important questions that need to be resolved. First, a comprehensive understanding of how mutant IDH alters chromatin states is lacking and needs to be established. Second, it is not known whether epigenomic reprogramming caused by mutant IDH is reversible and, if so, what the kinetics of reversibility are. Here we present a comprehensive picture of transcriptional and epigenomic dynamics that dissects the complex molecular reprogramming associated with mutant IDH1. The data show that mutant IDH1 reprogramming of the epigenome and transcriptome is dynamic, characterized by reversibility and partial persistence despite withdrawal of mutant IDH1. Furthermore, a decoupling between normal transcriptional and epigenetic states occurs upon loss of mutant IDH1 expression.
Results
Transcriptional dynamics associated with IDH1 R132H expression. We performed multi-'omic' analyses of engineered immortalized human astrocytes (IHAs) and patient-derived glioma tumorspheres to characterize the dynamics and reversibility of epigenetic and transcriptional changes induced by IDH1 Arg132His (R132H) (Fig. 1a) . We constructed a tetracycline-inducible expression system (Fig. 1b,c ) and passaged IHAs in the presence of doxycycline for 30 passages (considered as baseline). We profiled these cells for 1, 5, 10, 20 , and 40 passages following doxycycline withdrawal with gene expression and methylation arrays (Fig. 1d ). For IHAs with inducible expression of mutant IDH1 at baseline (Dox + ), starting at ten passages following doxycycline withdrawal, cells in the doxycycline withdrawal state (Dox off ) were similar to cells that had never been exposed to doxycycline (Dox -) (Fig. 1e ). Control IHAs with doxycycline-inducible empty vector did not exhibit significant doxycycline-dependent changes in gene expression ( Supplementary Fig. 1a,b) . To dissect gene expression dynamics, we identified clusters of genes with transient, gradual, and persistent changes in gene expression following doxycycline withdrawal (Supplementary Table 1 ). Coherent clusters included 193 downregulated probes (151 genes) (73.6% transient, 16 .6% gradual, and 9.8% persistent) (Fig. 1f , left) and 243 upregulated probes (205 genes) (64.2% transient, 30% gradual, and 5.8% persistent) (Fig. 1f, right) . Persistently upregulated genes-whose expression was independent of IDH1 R132H after doxycycline withdrawal-included L1CAM, MTUS1, and WNT6 (Fig. 1g, top) . L1CAM, a neural cell adhesion molecule with roles in normal brain development, is upregulated in gliomas and preferentially expressed in glioma stem cells [9] [10] [11] [12] . Several transcription factors, including MAF, MEOX2, and NKX2-1, were persistently downregulated (Fig. 1g, bottom) . L1CAM was upregulated (P = 7.5 × 10 −8
) and MEOX2 was downregulated (P = 4.6 × 10 −9 ) in IDH-mutated LGGs, and these genes may have a role in glioma pathogenesis ( Supplementary Fig. 1c ). The magnitude of the fold change in expression at baseline was a major determinant of gene a, Summary of the cellular models used to study IDH1 R132H function and the epigenomic and transcriptomic datasets produced in this study. b, IHAs transduced with inducible empty vector (EV) or vector encoding wild-type (WT) or R132H (MUT) IDH1 were grown for 30 passages (baseline) in the presence (+ ) or absence (-) of 1 μ g/ml doxycycline. Doxycycline was withdrawn from the medium for either two (top) or ten (bottom) passages after baseline (off). Western blot analysis of inducible IHAs confirms expression of IDH1 R132H only in the presence of doxycycline. c, Total intracellular 2HG was measured by gas chromatography coupled with mass spectrometry and normalized to an internal standard (D5-2HG) and cell number. 2HG levels are increased upon doxycycline administration and are completely inhibited at 15 passages following doxycycline withdrawal after baseline. expression reversibility (P = 0.0026 for upregulated genes and P < 2.2 × 10 −16 for downregulated genes) ( Supplementary Fig. 1d ). To assess the relevance of our findings, we compared gene expression and methylation changes to those observed in IDH-mutant gliomas 5 , finding similarly deregulated pathways in IHAs inducibly expressing mutant IDH1 and CpG island methylator phenotype positive (CIMP + ) gliomas (Supplementary Fig. 2a) . Furthermore, hypermethylated loci in IHAs with inducible expression of mutant IDH1 displayed increased median methylation in CIMP + LGGs as compared to CIMP − LGGs (Supplementary Fig. 2b ). Interestingly, our study identified mutant-IDH1-dependent upregulation of CD24, which encodes a putative cell-surface marker for stem-like cell populations 13 that is overexpressed in tumors and broadly expressed in many tissues, including the brain 14 ( Fig. 1h) . In IHAs inducibly expressing mutant IDH1, CD24 was upregulated as compared to non-induced cells, and its expression was decreased upon doxycycline withdrawal ( Fig. 1h and Supplementary Fig. 2c ). We confirmed higher CD24 expression in a cohort of CIMP + LGGs (Supplementary Fig. 2d) Table 2 ). Gene set enrichment analysis (GSEA) showed positive enrichment of cholesterol biosynthesis, MYC target, WNT signaling, and embryonic stem cell core pathways, demonstrating a stem cell-like gene expression program in CD24 + cells ( Supplementary Fig. 2g ). Methylation analysis identified 16,525 hypermethylated and 20,260 hypomethylated loci in CD24 + IHAs relative to CD24 -IHAs (Supplementary Table 2 ). Overall, 137 downregulated and 189 upregulated genes had a CpG probe whose methylation was inversely correlated with their expression in CD24 + and CD24
-cells (Fig. 1i and Supplementary Table 2 ). We used RNAseq data from the BrainSpan Developmental Transcriptome 15 to determine the expression patterns of genes upregulated in CD24 + IHAs during human brain development. Several genes, including CD24P4, L1CAM, and GNAL, were expressed at higher levels in the prenatal brain and the brain during early infancy as compared to adult brain (Fig. 1j) . Notably, L1CAM is an interaction partner of CD24 and can promote self-renewal, tumorigenesis, and proliferation in gliomas 9, 16, 17 . Taken together, these data suggest that CD24
+ cells emerge in a progenitor-like state from astrocytes expressing IDH1 R132H and this process may contribute to epigenetic and transcriptional reprogramming.
Dynamic reshaping of chromatin landscape by IDH1 R132H.
ChIP-seq analysis of major histone modifications showed progressive enrichment of H3K4me3 (associated with actively transcribed genes), H3K36me3 (preventing intragenic cryptic transcript initiation during active transcription), and H3K9me3 and H4K20me3 (repressive marks enriched in heterochromatic regions) in successive passages of IHAs with stable expression of IDH1 R132H but not in parental astrocytes (Fig. 2a,b) . We inspected the chromatin reorganization of H3K9me3, H4K20me3, and H3K36me3 using Hilbert curves 18 , which showed mutant-IDH1-specific spread over additional genomic regions ( Supplementary Fig. 3a ). To determine histone methylation kinetics, we grouped the union of peaks across all cell lines with stable mutant IDH1 expression per histone mark by k-means clustering into six clusters. Regions within H3K4me3 cluster 1 exhibited the highest intensity across all passages and were mostly located within 5′ UTRs or promoter regions ( Supplementary  Fig. 3b ), whereas regions in cluster 6, which showed enrichment in mutant-expressing astrocytes at passage 40, were mostly located in introns or intergenic regions ( Fig. 2c and Supplementary Fig. 3b ). Clustering of H3K9me3 and H3K36me3 peaks identified regions with similar enrichment across all samples (cluster 5 for both H3K9me3 and H3K36me3) and regions with uniformly high enrichment for H3K9me3 (cluster 2 and cluster 6) or H3K36me3 (cluster 1 and cluster 6) in mutant-expressing astrocytes at passage 40 ( Fig. 2c,d ). Next, we divided the genome into 5-kb sliding windows, calculated H3K9me3 and H3K36me3 enrichment for each window, and identified six distinct groups using k-means clustering. This unbiased approach also identified genomic regions with increased H3K9me3 and H3K36me3 signal in mutant-expressing astrocytes at passage 40, whereas larger regions were quiescent for these histone marks at the same passage ( Supplementary Fig. 3c-e) . These results indicate that increased H3K9me3 and H3K36me3 methylation occurs at specific regions, rather than uniformly across the genome ( Supplementary Fig. 3c-e) .
While there was an overall increase in H3K36me3, H3K9me3, and H4K20me3 in IHAs expressing mutant IDH1, the proportions of overlapping genomic features for these marks remained approximately equivalent to those in parental cells (Supplementary Fig. 4a ). In contrast, the distribution of H3K4me3 peak locations extended to intronic and intergenic regions in IHAs expressing IDH1 R132H (Fig. 2e) . Notably, we observed focal H3K4me3 gains at 4q12 in mutant-expressing astrocytes, including increased H3K4me3 within the DANCR locus and the transcriptional start site (TSS) of PDGFRA, an oncogene intimately linked to gliomagenesis 19 ( Fig. 2f ). We analyzed bulk histone methylation levels in IHAs with inducible expression of mutant IDH1 by liquid chromatography coupled with mass spectrometry of purified histones, confirming significant increases in H3K4me2, H3K4me3, H3K9me2, H3K9me3, and H3K36me3 in Dox + IHAs (Supplementary Fig. 4b ). To determine the reversibility of the changes in the histone methylation landscape, we performed ChIP-seq on H3K4me3, H3K27me3, H3K9me3, and H3K36me3 at baseline and at 40 passages following doxycycline withdrawal. As for IHAs stably expressing mutant IDH1, we observed substantial H3K4me3 enrichment along with increases in H3K36me3 and H3K9me3 in Dox + IHAs relative to Dox -IHAs at baseline (although the increases were more modest than those in IHAs with stable expression) (Fig. 2g) .
To determine the chromatin state organization in IHAs expressing mutant IDH1, we used ChromHMM 20 to learn genomewide combinations of H3K4me3, H3K36me3, H3K27me3, and H3K9me3 in IHAs with stable and inducible expression (Fig. 2h,i) . In IHAs stably expressing mutant IDH1, we identified states largely devoid of histone marks (states 1-3) with differential genome coverage and enrichment. Predominant features (> 20% emission probability, defined as the probability of finding a histone mark in a given state) for other states included H3K36me3 + H3K9me3 (state 4), H3K36me3 + H3K9me3 + H3K27me3 (states 5 and 6), all features (state 7), H3K9me3 + H3K27me3 (state 8), H3K9me3 + H3K27me3 + H3K4me3 (state 9), and H3K4me3 (state 10). Similarly, in IHAs with inducible expression, states 1, 3, and 6 did not have any histone marks (Fig. 2i) , states 4 and 5 had features of all histone marks, and state 2 was marked by H3K36me3 + H3K9me3 + H3K27me3. Features for other states included H3K36me3 + H3K27me3 (state 7), H3K36me3 with high enrichment in exonic regions (state 8), H3K9me3 + H3K36me3 (state 9), and H3K4me3 (state 10) (Fig. 2i) . Chromatin state analysis showed a time-dependent increase in genome coverage of state 5 in IHAs with stable expression of mutant IDH1 (6.7% of the genome covered after 40 passages) (Fig. 2h) . A similar chromatin state in IHAs with inducible IDH1 expression (state 5) exhibited higher genome coverage in Dox + IHAs (3.2%) (Fig. 2i ). In addition, there was a greater percentage of IHAs stably expressing mutant IDH1 in state 2, which is marked by low levels of H3K36 signal (Fig. 2h) P a r P 1 0 P a r P 2 P a r P 4 0 M u t P 2 M u t P 1 0 M u t P 4 0 P a r P 1 0 P a r P 2 P a r P 4 0 M u t P 2 M u t P 1 0 M u t P 4 0 P a r P 1 0 P a r P 2 P a r P 4 0 M u t P 2 M u t P 1 0 M u t P 4 0 T r a n s ie n t G r a d u a l P e r s is t e n t T r a n s ie n t G r a d u a l P e r s is t e n t D o x o 4 0 P P a r e n t a l P 4 0 T S 6 0 3 M u t a n t P 4 0 (Fig. 2i) . These results show dramatic, specific, and dynamic histone mark reorganization in the presence of IDH1 R132H.
Mutant-IDH1-induced DNA methylation is gradually reversible, but a fraction of the genome exhibits persistence. Next, we compared the DNA methylation profiles of Dox + and Dox -inducible IHAs at baseline. Overall, 41,209 loci were differentially methylated, of which 67.4% were hypermethylated (n = 27,792). Notably, 18,023 of the hypermethylated loci displayed at least 70% methylation in a patient-derived glioma tumorsphere harboring mutation of endogenous IDH1 encoding the R132H mutant (TS603) (P = 1 × 10
), suggesting methylation gain across similar loci ( Supplementary Fig. 5a,b) . Unsupervised clustering of DNA methylation showed that, starting at 20 passages following doxycycline withdrawal, Dox off astrocytes were more similar to Dox -than to Dox + astrocytes (Fig. 3a) . Control IHAs with empty vector did not undergo doxycycline-dependent changes in methylation ( Supplementary Fig. 5c-e) .
While methylation at most loci eventually returned to baseline levels following doxycycline withdrawal, 25% of differentially methylated loci maintained their aberrant methylation levels (Fig. 3b) . Using an approach similar to that applied to delineate gene expression dynamics, we identified methylation clusters with time-dependent changes (Supplementary Table 3 (Fig. 3c,d) . As for the gene expression data, we observed a significant positive correlation between the magnitude of methylation changes and the degree of persistence (P < 2.2 × 10
−16
). Overall, 49% of loci with intermediate and 64.4% of loci with high gains in methylation were persistently hypermethylated (Fig. 3e) . Next, we binned persistently methylated loci by their baseline β values (DNA methylation percentage) in Dox − IHAs ( Supplementary Fig. 6a,b) . Most of these loci had intermediate methylation levels while 765 loci had less than 20% methylation in the baseline state ( Supplementary  Fig. 6a,b) . The median β-value difference (Δ β) for persistently methylated loci compared to baseline was a gain of 21% at the end of the doxycycline withdrawal time course (Supplementary Fig. 6c ). Select loci (n = 29) were unmethylated at baseline (< 10%) and maintained a > 30% increase at passage 40 after doxycycline withdrawal ( Supplementary Fig. 7a,b) .
Overlap of differentially methylated loci with Encyclopedia of DNA Elements (ENCODE) states 21 showed hypermethylation proximal to TSSs (states 1 and 2) and enhancer regions (state 7) and hypomethylation of quiescent regions (state 15) in IHAs with inducible expression of mutant IDH1 (Fig. 3f) . In the persistent state, hypermethylated loci were preferentially localized in promoter regions (states 1 and 2), whereas 52.3% of hypomethylated loci were located within the quiescent genome (state 15).
We sought to determine whether any correlation existed between altered gene expression and the epigenetic state in IHAs inducibly expressing mutant IDH1 (Fig. 3g) . Downregulated genes in the gradual and persistent gene expression clusters tended to have a tighter hypomethylated β-value distribution within their intergenic regions (Fig. 3g) . We plotted ChIP-seq signals ± 1 kb around CpG sites corresponding to either all probes, to generate background signal, or methylation clusters ( Supplementary Fig. 8a,b) . Persistently hypermethylated loci exhibited slightly increased surrounding H3K4me3 signal in Dox -cells relative to Dox + cells at baseline and were largely depleted of H3K27me3, H3K36me3, and H3K9me3 ( Supplementary Fig. 8b ). In contrast, persistently hypomethylated loci had low H3K4me3 signal (similar to other clusters) but exhibited increased signal (with low enrichment) for H3K27me3, H3K36me3, and H3K9me3 in Dox -cells (Fig. 3h) . It is important to note that all three gene expression clusters had an overall higher H3K4me3 signal surrounding hypomethylated CpG sites in Dox + versus Dox -cells, suggesting a shift in H3K4me3 toward regions that lose methylation (Fig. 3h) . Overlap of chromatin states with aberrantly methylated loci indicated differences between the chromatin states associated with hypermethylated and hypomethylated loci; however, we did not observe a chromatin state common among persistent clusters (hypo-and hypermethylated), with the exception that hypomethylated loci in the persistent cluster overlapped minimally (1% of persistently hypomethylated loci) with chromatin state 10 (marked by high H3K4me3 enrichment at TSSs) (Fig. 3i) . These findings suggest that the small set of genes whose expression continues to be perturbed after withdrawal of IDH1 R132H are likely to be indirectly regulated by mutant IDH and that maintenance of an aberrant chromatin state is not necessary for persistent changes in gene expression.
Gain of H3K4me3 and loss of DNA methylation at regions with quiescent chromatin states. ChromHMM analysis showed lowto-intermediate enrichment levels of H3K4me3 co-occurring with other states such as H3K27me3 + H3K9me3 + H3K36me3, pointing to aberrant coexistence of chromatin states in cells expressing mutant IDH1 (Fig. 2h,i) . One such state, state 5 with higher genome coverage in Dox + IHAs, was largely distributed among intronic and intergenic regions (Fig. 4a) . While several Dox − chromatin states (states 1, 6, and 10) were maintained in Dox + samples, others showed shifts in their composition (Fig. 4b) . Overall, in Dox − and Dox + inducible IHAs, H3K4me3 signal displayed a positive correlation with gene expression (Supplementary Fig. 9a ) and, when TSSs were ranked by H3K4me3 occupancy across both inducible lines, the expression of several genes, including PDGFRA and CD9 with higher H3K4me3 ranking in Dox + samples, was also upregulated by more than 1.5-fold (Supplementary Table 4) .
Although most H3K27me3, H3K9me3, and H3K36me3 peaks reverted to baseline levels following doxycycline withdrawal ( Supplementary Fig. 9b ), a distinct proportion of the sites at which H3K4me3 peaks were gained in Dox + IHAs maintained their aberrant histone methylation (Supplementary Fig. 9c ). Of note, 37% of genes with decreased H3K4me3 signal were also persistently hypermethylated, including MAP1LC3A, MARVELD2, and TET1 ( Supplementary  Fig. 9d ). RNA-seq data indicated a strong reduction in expression of the autophagy-related gene MAP1LC3A that was maintained upon doxycycline withdrawal (Fig. 4c and Supplementary Table 5) .
We derived the 11,443 regions with the most significant H3K4me3 gain in Dox + IHAs inducibly expressing mutant IDH1 relative to Dox -IHAs (Supplementary Table 6 ). These regions were largely devoid of H3K4me3 in Dox -cells and maintained low-level H3K4me3 signal in the Dox off state (Fig. 4d) . A majority of regions that gained H3K4me3 with mutant IDH1 expression were enriched for intergenic and intronic regions (Fig. 4e,f) .
To further explore IDH1 R132H-specific chromatin alterations associated with H3K4me3, we performed ChIP-seq for H3K4me3 on TS603 and two IDH-wild-type tumorspheres (TS543 and TS667). GSEA using the GREAT toolbox of the genes corresponding to the top 2,000 H3K4me3 peaks at TSSs for all profiled cells identified several enriched gene sets in IDH-mutant but not IDH-wild-type cells, including MYC/MAX targets and ZNF143 binding, implicating MYC signaling 22, 23 and aberrant chromatin interactions in IDH-mutant cell lines (Fig. 4g) . Furthermore, differential enrichment analysis of models with mutant versus wild-type IDH1 identified 1,159 H3K4me3-binding sites that separated cell lines on the basis of IDH1 R132H status, and aberrant H3K4me3 remained at lower enrichment levels in the Dox off state for these differentially enriched regions (Fig. 4h, Supplementary Fig. 9e , and Supplementary Table 6 ). , and tumorspheres (TS543, TS603, TS667) (gray). The scale corresponds to the z scores of regularized log-transformed read counts. Regularized logtransformed (rlog) is a function that transforms RNA-seq read counts. d, qPCR validation of select ERVs (from c) with increased expression in Dox + IHAs at passage 70. Error bars, s.d; n = 3; **P < 0.01, ***P < 0.001, ****P < 0.0001; n.s., not significant (unpaired t test). e, Heat map of viral defense signature genes 25 
Upregulated viral defense signatures, endogenous retroviruses, and genome instability in IDH1 R132H-expressing astrocytes.
We hypothesized that H3K4me3 gain and DNA methylation loss at intergenic regions might poise repetitive elements located at methylation-dense, quiescent genomic regions for activation. GSEA indicated a highly significant positive enrichment of genes within the interferon (IFN)-α response pathway gene set in astrocytes with inducible expression of mutant IDH (Fig. 5a,b) . Given the upregulated interferon response, we considered whether endogenous retroviruses (ERVs) might be reactivated in response to IDH1 R132H expression. As described previously 24 , we mapped our RNA-seq data to a family of expressed ERVs and identified specific ERVs (for example, ERVH-2, ERVH-4, ERVH-6, and ERVH-5) with elevated expression in mutant-IDH-expressing samples, but not in control cells, upon long-term culturing (at the end of the time course, 70 passages) (Fig. 5c) . We validated several of these ERVs by qPCR (Fig. 5d) . Additionally, a previously described viral defense signature 25 was upregulated in IHAs inducibly expressing mutant IDH1, as well as in a subset of IDH1-mutant LGGs (Fig. 5e and Supplementary Fig. 10a ). We tested expression of ERVs previously described to trigger an immune response 26 and observed a modest but significant increase in expression for several of these ERVs (Fig. 5f ). Therefore, it appears that IDH1 R132H may have a role in upregulating ERVs, which may contribute to genome instability or immune activation 25 .
On the basis of the observations above, we wondered whether mutant IDH1 could promote genetic instability. GSEA indicated aberrant enrichment of several positional gene sets in Dox + IHAs, including negative enrichment of chromosome 19q13 genes (Fig. 5g) . Analysis of copy number alterations using methylation data identified amplifications and deletions of several regions, including a higher frequency of broad deletions of chromosome 19q, in Dox + IHAs inducibly expressing mutant IDH1 as compared to Dox -IHAs, but not in controls with empty vector (Fig. 5h and Supplementary  Fig. 10b,c) . Chromosome 19q loss (with intact 1p) occurs in gliomas and may be a negative prognostic marker 27 . Metaphase FISH confirmed our finding of an increased frequency of 19q loss in mutant-IDH1-expressing IHAs (Fig. 5i) . Loss of 19q occurred primarily via unbalanced translocation or rarely by isochromosome of 19p.
In vitro and in vivo phenotypic persistence associated with IDH1 R132H expression. We asked whether mutant-IDH1-associated phenotypes required continued presence of IDH1 R132H. Consistent with previous studies 28 , Dox + IHAs exhibited defective contact inhibition and increased proliferation despite confluence (Fig. 6a) . Strikingly, loss of contact inhibition was highly dependent on IDH1 R132H expression in vitro and returned to the normal state within six passages of doxycycline withdrawal, at a faster pace than for epigenetic and transcriptional reversion (Fig. 6a) . This suggests that contact inhibition abrogation requires continued mutant IDH1 expression. To examine whether mutant IDH1 is required for tumor maintenance, we implanted the inducible IHAs into the forebrains of NOD-SCID mice. Animals were placed on a doxycycline-containing diet to induce IDH1 R132H expression. Two months after implantation, mice were randomized on the basis of bioluminescence signal (BLI): ten mice continued on doxycycline and ten mice returned to regular mouse feed. BLI measurements indicated a small (albeit not statistically significant) reduction in tumor growth after doxycycline withdrawal (Fig. 6b) . None of the mice injected with control IHAs developed tumors ( Supplementary  Fig. 11a ), while several mice (~40%) injected with Dox + IHAs displayed intracranial lesions on magnetic resonance imaging (MRI) (Supplementary Fig. 11b,c) .
To better understand the morphology of these tumors, we used serial two-photon tomography (STPT) to image ZsGreen fluorescence (marker for injected inducible IHAs) throughout the brain.
Cells positive for green fluorescence were automatically detected ( Fig. 6c) and reconstructed in 3D (Fig. 6d and Supplementary  Videos 1-3) , and their spatial information was registered to a 3D reference brain based on the Allen Brain Atlas to extract structural information (Fig. 6e) 29, 30 . While clusters of injected Dox -cells were not apparent by MRI, mouse brains injected with these cells displayed several bright areas on STPT slices ( Supplementary  Fig. 11d ). Semiquantitative analysis of a representative STPT image showed that the majority of cells were present at the injection site (somatosensory cortex) and spread into nearby regions, with growth in dorsal striatum (Fig. 6e) . Notably, we identified several brains with parenchymal infiltration of mutant-IDH1-expressing astrocytes observed at cellular resolution that were not apparent on MRI images (Supplementary Fig. 11e) . Overall, our results indicate that IHAs with IDH1 R132H have a greater potential to infiltrate and form tumors in an orthotopic model; however, tumors continue to grow when IDH1 R132H is removed.
Discussion
We have assembled an atlas of integrated longitudinal epigenomic and transcriptomic data from IDH1 R132H-expressing glial systems to map a detailed landscape of global remodeling and reversibility associated with IDH1 mutations. Although IDH1 mutation results in progressive accumulation of methylation marks on DNA and histones, subsequent suppression of mutant IDH1 expression does not result in the epigenome and transcriptome completely returning to the original state (at least over the time period tested). Our findings suggest alternate effector pathways associated with IDH mutations that may eventually be decoupled from the neomorphic enzymatic activity of mutant IDH protein. This is intriguing given previous findings that 2HG inhibition alone is not sufficient to reverse the mutant-IDH-induced epigenetic state 7, 8, 31 . Our data also show the slow nature of methylation changes upon loss of mutant IDH1 and highlight the need for experiments with longer time courses using mutant IDH1 inhibitors to determine its long-term effects together with the utility of combining epigenetic drugs with small-molecule inhibitors of mutant IDH1.
We identified L1CAM as being persistently upregulated despite long-term loss of mutant IDH1 expression, suggesting that continued L1CAM expression might contribute to the oncogenic phenotype conferred by mutant IDH1. Previous studies have shown that L1CAM is expressed on glioma stem cells and that its suppression leads to reduced tumor growth in intracranial brain tumor xenograft models 9 . Further research into L1CAM inhibition in IDHmutant gliomas, perhaps with L1CAM-blocking antibodies, may be considered as a means to sensitize therapeutic response to mutant-IDH-specific inhibitors.
Our results show that, in addition to repressive chromatin marks such as H3K9me3, there is enrichment of activating histone marks (such as H3K4me3) upon expression of mutant IDH1, highlighting the importance of understanding the chromatin landscape in IDHmutant gliomas. Our data also show that loss of DNA methylation in mutant-IDH1-expressing astrocytes occurs more frequently in regions marked by a quiescent/low chromatin state. Interestingly, DNA hypomethylation has been observed in IDH1-mutant cell line models and in recurrent IDH1-mutant gliomas, suggesting that these hypomethylated regions may have a role in initiation or progression of IDH-mutant gliomas 6, 23 . H3K4me3 enrichment and loss of DNA methylation at quiescent genomic regions may indicate the presence of an open and dynamic chromatin state that can lead to aberrant recruitment of transcription machinery and transcriptional activation of noncoding RNAs such as ERVs. Our observation that loss of 19q is accelerated in IDH1 R132H-expressing astrocytes suggests that, collectively, deregulation of histone marks and DNA methylation, and possibly activation of ERVs, may lead to genomic instability. We demonstrate gain in H3K4me3 at the PDGFRA promoter in IDH1 R132H-expressing astrocytes as early as passage 2. PDGFRA is overexpressed in gliomas, and previous work has shown that IDH mutations disrupt enhancer boundary function, leading to PDGFRA activation 32 . An early H3K4me3 gain may poise PDGFRA for activation before genome-wide hypermethylation is established or may act together with reduced CTCF binding to achieve PDGFRA activation. These data suggest that PDGFRA signaling may be poised for activation as an early event in IDH1-mutant gliomas.
We also identified a CD24 + stem cell-like subpopulation with distinct molecular alterations within IDH-mutant cells. In soft agar assays, we observed the increased potential for colony formation of the CD24 + subpopulation, although further experimental confirmation is needed to establish a direct link between CD24 status and increased clonogenic ability. These results highlight the importance of higher-resolution sequencing approaches to identify subpopulations within IDH-mutant tumors that may ultimately contribute to recurrence or treatment resistance. Our findings show that mutant IDH1 inhibition by doxycycline withdrawal leads to a modest decrease in tumor growth in a brain orthotopic model of IDH1 R132H-expressing IHAs. While inhibition of mutant IDH1 is likely to offer benefit, there is a need to identify and target additional pathways to control growth of IDH-mutated tumors.
In summary, the integrated data presented here provide new insights into transcriptional and epigenetic dynamics associated with IDH1 mutations in unprecedented detail and may be useful for IDH-related studies and for the development of novel therapies for glioma.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0001-z.
Cell culture. Immortalized human astrocytes were a gift from R. O. Pieper (UCSF) and were generated as previously described 33 . IHAs were infected with pLVX-TetOn retrovirus and selected with 800 μ g/ml G418. Selected IHAs were infected with either empty pRetroX-hygro or pRetroX-hygro containing the coding sequence for IDH1 R132H cloned downstream of the Tet-responsive promoter and selected with 500 μ g/ml hygromycin B. IHAs were cultured in the presence of doxycycline to induce expression of IDH1 R132H or in its absence (one passage equivalent to two doublings). Gliomaspheres (TS603, TS543, and TS667) were derived from patients undergoing tumor resection at Memorial Sloan Kettering Cancer Center (MSKCC). Tumors were obtained in accordance with institutional review board policies at MSKCC. Glioma tumorsphere lines were maintained in Neural Stem Cell (NSC) Basal Medium with NSC proliferation supplements, 10 ng/ml EGF, 20 ng/ml bFGF, and 2 μ g/ml heparin (StemCell Technologies). All cell lines were routinely tested for mycoplasma and found to be negative. TS603 is a World Health Organization (WHO) grade III oligodendroglioma line with 1p/19q co-deletion and a mutation in endogenous IDH1 encoding R132H, and TS543 and TS667 are malignant glioma tumorsphere lines and harbor PDGFRA amplifications 7, 34 . FACS analysis. Inducible IHAs at passage 50 were stained for 30 min on ice in the dark with antibody to CD24 (BD Biosciences, 555427), and dead cells were excluded by DAPI staining. Cells were washed in PBS and analyzed using a FACSAria III (Becton Dickinson).
Sample preparation. Genomic DNA was extracted with the DNeasy Blood and Tissue kit (Qiagen), and RNA was isolated with the RNeasy Plus Mini kit.
Histone extraction and mass spectrometry. Histones from 5 million cells per sample were extracted using a standard acid extraction protocol. Histone modification was quantified using a bottom-up mass spectrometry strategy as outlined previously 35 . Briefly, the histone pellet washed in ice-cold acetone was air dried and then subjected to trypsin digestion and chemical derivatization using propionic anhydride as described previously 36 . Histone peptides were then analyzed by nano-liquid chromatography coupled with triple-quadrupole mass spectrometry (Dionex UltiMate 3000 and Thermo Fisher Scientific TSQ Quantum) using the selected reaction monitoring (SRM/MRM) method developed previously 37 . Data were analyzed using Skyline software (MacCoss Lab, University of Washington) 38 .
Proliferation assays. Cell proliferation was measured in duplicate using xCELLigence RTCA DP (ACEA Biosciences) (cell index). Cells were seeded at a density of 10,000 cells/well on 16-well plates (E-Plate, ACEA Biosciences) in a humidified chamber at 37 °C and 5% CO 2 , and the cell index was monitored for 150 h. Experimental results were exported using xCELLigence RTCA software (v 1.2.1).
Soft agar assays. Sorted cells (100,000 cells per sample) were plated in growth medium into six-well plates containing 0.65% top and bottom agar. Cells were plated in the middle layer in growth medium containing 0.40% agar. The medium covering the agar was refreshed every 3 d using medium with or without doxycycline (1 µ g/ml). After 2-4 weeks, colonies were stained with 0.0005% crystal violet and quantified using a Gelcount colony counter (Oxford Optronix).
Bioluminescence imaging. Cell lines for use in orthotopic in vivo experiments
were labeled with pHIV-Luc-ZsGreen (a gift from B. Welm (University of Utah), Addgene plasmid 39196). Transduced IHAs were sorted for ZsGreen expression. Bioluminescence imaging was performed weekly following intraperitoneal injection of d-luciferin, and signal was measured using the Xenogen IVIS Spectrum in vivo imaging system (PerkinElmer). Living Image software (PerkinElmer) was used to acquire and analyze the bioluminescence data.
Orthotopic transplantation experiments.
All mouse experiments were approved by the Institutional Animal Care and Use Committee at MSKCC, and strict guidelines were enforced. Female NOD-scid IL2Rg null mice (Jackson Laboratory) that were 5-6 weeks of age were intracranially injected with 5 × 10 5 cells overexpressing pHIV-Luc-ZsGreen using a fixed stereotactic apparatus (Stoelting). Injections were made to the right frontal cortex, 1.5 mm lateral and 1 mm caudal and at a depth of 2 mm with respect to bregma. Mice were fed either normal diet or doxycycline-containing chow (doxycycline hyclate diet formulated at 2,500 mg/kg; Envigo). Randomization of mice receiving the doxycycline diet was done as follows. Briefly, animals were ranked according to their bioluminescence signal and alternately assigned to group 1 (continued on the doxycycline diet) or group 2 (doxycycline diet withdrawn, continued on regular diet). Designation of diet conditions for either group was determined randomly in Microsoft Excel. Animals that were sick or died as a result of unrelated circumstances were excluded from further analyses. Lesions were analyzed by a board-certified neuropathologist (J.T.H.), and morphology, degree of infiltration, and cellularity were used as criteria for histopathology assessment.
FISH. Cell lines were harvested according to standard procedures. Briefly, cell lines were cultured with Colcemid (0.1 μ g/ml) at 37 °C for 45 min, resuspended in 0.075 M KCl, incubated at 37 °C for 10 min, and then fixed in methanol:acetic acid (3:1) solution. FISH analysis was performed on the fixed cells using a fourcolor 1p36/1q23 and 19p12/19q13 homebrew probe mix. The probe mix consisted of BAC clones mapping to the following loci: 1p36.32 (RP4-785P20; labeled with Red dUTP), 1q23.3 (RP11-1038N13, RP11-1059C21; labeled with Aqua dUTP), 19p12 (RP11-359H18, CTD-2502P8; labeled with Orange dUTP), and 19q13.3 (CTD-2639E6, RP11-960B2; labeled with Green dUTP). Probe labeling, hybridization, washing, and fluorescence detection were performed according to standard procedures. Slides were scanned using a Zeiss Axioplan 2i epifluorescence microscope equipped with a megapixel CCD camera (CV-M4 + CL, JAI) controlled by Isis 5.5.9 imaging software (MetaSystems Group). The entire hybridized area was scanned under 63× /100× to assess the quality of hybridization and the signal pattern. A minimum of 50 consecutive intact metaphases were captured, and signal counts (copy number) for each locus were recorded. A metaphase was considered to be positive for loss of 1p or 19q if the signal count (copy number) of the respective control locus was greater (relative loss).
Array-based genomic analysis. Expression analysis was performed using the Affymetrix U133 2.0 microarray, and methylation analysis was performed using the Illumina Infinium HumanMethylation450K bead array. Arrays were processed at the Integrated Genomics Operation (iGO) at the MSKCC according to the manufacturer's protocol. R statistical software 39 (v3.3.1) was used for data analysis. The ChAMP methylation pipeline (version 1.10) was used to extract and analyze data from idat files, and normalization was carried out using beta-mixture quantile normalization 40 . Batch correction was performed using the ComBat algorithm 41 . Δ β values were calculated by comparing Dox + to Dox -samples for IHAs with inducible expression of mutant IDH1 at the baseline passage. Loci with absolute Δ β > 0.1 were considered to be aberrantly methylated and were binned as follows: low, 0.1 < absolute Δ β < 0.2; intermediate, 0.2 ≤ absolute Δ β < 0.4; high, absolute Δ β ≥ 0.4. For overlap with ENCODE chromatin state models, we obtained chromatin core 15-state data for the NH-A ENCODE cell line (Epigenome ID E125).
Affymetrix CEL files were imported into R statistical software. Normalization was performed with the AffyPLM package in Bioconductor (v3.3), using RMA background correction, quantile normalization, and the Tukey biweight summary method. Batch correction was performed using the ComBat algorithm by incorporating batch information. To identify genes or loci specific to mutant IDH1, we excluded probes with equal or greater fold changes or Δ β in Dox + versus Dox . For gene expression in CD24-defined subpopulations (n = 2 replicates), normalization was performed as described above and differentially expressed genes were identified using the limma package. Genes with absolute fold change > 1 and FDR-adjusted P value < 0.05 were considered to be significantly differentially expressed.
To identify the CpG loci with the most impact on gene expression, the methylation probes with the most negative difference (Δ β < − 0.1) corresponding to upregulated genes or the most positive difference (Δ β > 0.1) corresponding to downregulated genes were identified. Genomic features associated with these probes were extracted from the Infinium HumanMethylation450K annotation file.
To derive gene expression clusters, genes with an absolute fold change > 1 (log 2 scale) in Dox + samples as compared to Dox -samples at baseline were identified and their fold change was determined at consecutive doxycycline withdrawal time points by comparing to baseline Dox -samples. We define genes that returned to baseline values (absolute fold change < 1 when compared to Dox off samples) within 5 passages as 'transient' , within 20 passages as 'gradual' , and that remained aberrantly expressed at 40 passages as 'persistent' . Aberrantly expressed genes at baseline (absolute fold change > 1) were binned as follows: low, absolute fold change < 1.5; intermediate, 1.5 < absolute fold change < 2; high, absolute fold change > 2. The significance of fold changes across clusters was determined using Fisher's exact test for count data. As for gene expression clusters, we derived methylation clusters with similar kinetics following doxycycline withdrawal. To this end, we considered loci with absolute Δ β > 0.1 as aberrantly methylated at baseline and set an absolute Δ β cutoff of 0.1 for cluster binning. In addition, subgroups of loci within the persistent cluster that maintained absolute Δ β ≥ 0.1 at passage 40 following doxycycline withdrawal were identified.
Copy number alterations. Copy number alterations were called from the Infinium HumanMethylation450K array using the ChAMP or conumee package in R statistical software 40, 43 . Segmented data were visually inspected and subsequently used to identify broad and focal copy number alterations in GISTIC2.0 44 on the GenePattern server with the --armpeel and --broad parameters set to "yes". Describe any data exclusions. Mice that were sick or died due to circumstances unrelated to the study were excluded from further analyses.
Replication
Describe whether the experimental findings were reliably reproduced. All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Randomization of the mice receiving dox diet were done as follows: Briefly, animals were ranked according to their BLI signal and alternatingly assigned to group 1 (continued on dox diet) or group 2 (dox diet withdrawn, continued on regular diet). Designation of diet conditions to either group was determined by randomly in Microsoft Excel (Microsoft).
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Pathologist was blinded to sample groups while describing mouse tumor pathology.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly.
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. p values) given as exact values whenever possible and with confidence intervals noted A summary of the descriptive statistics, including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
